InsidersTradesSigma
申报总数
公司
▲ 买入（2 笔）
▼ 卖出（0 笔）
内部人交易记录
董事已披露买入
2
已披露卖出
0
T+90 胜率
100%
T+90 平均收益
+34.4%
基于 1 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
信号历史
Browse the detailed record of transactions filed by Mulroy Michael H., 董事. Director active across 1 company, notably Lineage Cell Therapeutics, Inc.. Aggregated, 3 filings have been published. Split: 2 buys · 0 sell. Total volume traded: €31k. History available since 18 June 2021. The latest transaction was disclosed on 22 November 2024 (Acquisition). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to Mulroy Michael H.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报3 总计
40,000 股@ US$0.56617.8% 占其流量Common SharesSEC:0000950170-24-130592:0
标准退出：2025年2月20日 (T+90)
7,000 股@ US$1.4011.7% 占其流量Common Shares, no par valueSEC:0001493152-22-007754:0
标准退出：2022年6月22日 (T+90)
24,720 股@ US$2.2059.9% 占其流量Common Shares, no par valueSEC:0001493152-21-014860:0
3 条申报中的 3 条
About Mulroy Michael H.
Michael H. Mulroy is a Board Member at Lineage Cell Therapeutics, Inc. With expertise in the biotechnology sector, he oversees the development and innovation strategies of the company. His role is crucial in ensuring the growth and sustainability of Lineage.
